Social Media in Clinical Trial Recruitment & Retention



Similar documents
Understanding Clinical Trial Recruitment Rules

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

Using Social Media in Research: Regulatory and IRB Considerations

Core Training Outline

Principal Investigator and Sub Investigator Responsibilities

Use of Social Media by Pharmaceutical Medical Information Teams

Department of Health and Human Services. Final Guidance Document

Use of Electronic Health Record Data in Clinical Investigations

Social Media Research 101. By: Dorean J. Flores, CIP Manager, North Shore-LIJ IRB

Fair Balance on the Internet: A Review of Recent DDMAC Enforcement Action. By Alyson Sous, PharmD

Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products

No Page 1 of 5. Issue Date 4/21/2014

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)

INVESTIGATOR MANUAL. Table of Contents

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers

Transforming study start-up for optimal results

Human Subjects Research (HSR) Series

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

AAHRPP DOCUMENT # 84 UNIVERSITY OF ALABAMA HUMAN RESEARCH PROTECTIONS PROGRAM FORM: NOTIFICATION TO IRB OF EMERGENCY USE OF A TEST ARTICLE

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part IV Criteria for Review. Cindy Gates IRB Administration

International Medical Device Regulators Forum (IMDRF) US FDA Center for Devices and Radiological Health - Update

Centralized vs Onsite Monitoring:

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research

Documentation of the Informed Consent Process. USC Office for the Protection of Research Subjects (OPRS)

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Role of eclinical Systems in FDA Regulated Studies. Jonathan S. Helfgott

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Nova Southeastern University IRB - Consent Form Checklist Version Date: 02/17/2010

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research

How To Weigh Data From A Study

Final Guidance on Electronic Source Data in Clinical Investigations Promoting esource Data Capture

WARNING LETTER. J'A randomized comparison of Jversusl. _. J in patients undergoing early invasive management forl ] performed for C.

Clinical Research Professional Certification & Preparing for the CCRP Exam

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

IRB Submissions and Human Subjects Research Compliance. Georgia Health Sciences University

Adventist HealthCare, Inc.

HOUSE BILL NO. HB0208 A BILL. for. AN ACT relating to insurance; providing for the licensure

Essential Documents for the Conduct of a Clinical Trial. Debra Dykhuis Associate Director RSO

The Beginner Research Assistant/Coordinator (CRC) Track Basic Level

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

Guidance on IRB Continuing Review of Research

U.S. Food and Drug Administration

Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials

Introduction to Compliance with FDA Labeling and Advertising Requirements

ROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

INTERIM SITE MONITORING PROCEDURE

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB

RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS

How to Develop a Clinical Study Site Budget

BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE

Use of Electronic Health Records in Clinical Research: Core Research Data Element Exchange Detailed Use Case April 23 rd, 2009

Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical

Singapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY

Recruitment of Research Participants. Dorean J. Flores IRB Manager

Thomas Conroy, RPh., J.D. Director, Promotion Compliance Global Regulatory Affairs MARCH 11, 2015

Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation

Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs

Change of preference campaign Evaluation report

TeleSales Fast Start Package: Selling Silver Guard Using the INSpeed Enrollment Process

Guidance for Industry

Site Activation: Keep Your Eyes on the Prize

The Financial Advisor s Guide to Social Media Regulations

A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky

Comprehensive Study Documents List (Biomedical Studies)

Challenges and Opportunities in Clinical Trial Data Processing

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Guidance for Industry. IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Rehabilitation Counseling Program Department of Kinesiology and Community Health Evaluation Plan. Discrepancy Evaluation Model

Media Boot Camp for Patient Recruitment

LIBRARY GUIDE: Pharmaceutical Sales & Marketing

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Risk based monitoring using integrated clinical development platform

Engaging E-Patients in Clinical Trials through Social Media. Patient Recruitment and the E-Patient: A Survey Analysis

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

NEGOTIATING CLINICAL TRIAL BUDGETS. Debbie Williams R.N., C.C.R.C., C.R.A., A.B.N.

Ethical Principles in Clinical Research. Christine Grady Department of Bioethics NIH Clinical Center

When investigative sites are struggling with subject recruitment, and it

Patient Centric Monitoring Methodology

Transcription:

May 20, 2013, 4:00pm Social Media in Clinical Trial Recruitment & Retention Evan R. Hempel & Stephanie Millin 1

What is Social Media Forms of electronic communication (as Web sites for social networking and microblogging) through which users create online communities to share information, ideas, personal messages, and other content (as videos) (Merriam-Webster) 2

Social Media Changed the World 3

Not Just Social Media But Access to Social Media 4

Who Uses Social Networks? 5

Social Networks & Clinical Trials Recruitment Institutional Pages Targeted Advertisement Recruitment Specific Networks Retention Minimizing Lost-to-Follow-up Communication Tool 6

Recruiting with Social Networks Phase II study in Neonates of Efficacy, PK and Safety of an Investigational Product Study completed enrollment at nearly half the anticipated rate- 58% of expected time As compared to previous similar study without social network advertising that that took more than 300% of sponsor expected time. Site that used Facebook: Enrolled more than 3 times as many as any other site Total per subject cost was 15-30% lower 7

Retention with Social Networks On-going Longitudinal (16 year) Mental Health Clinical Study Several sites included within ICF permission to use Facebook to locate participants and conduct long term follow-up. 8

Other Roles for Social Media Networking of Clinical Trial Professionals Tweeting of advertisements Disease-specific support networks Educate about CT and importance 9

Smartphones and epro Smartphones have increased access Electronic Patient Reported Outcomes (epro) use mobile phone texting and smartphone app technology to allow direct data collection. 10

Why Use Social Media? Speed Cost Effective Leading Mode of Information Sharing Benefits of Social Support 11

Social Media Challenges 12

Regulatory Concerns with Social Media No clear FDA guidelines Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools (Nov. 2009)1 DRAFT Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices (Dec. 2011)2 1. Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools. 17 April 2013. FDA. 18 May 2013. <http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm184250.htm> 2. Guidance for Industry : Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices. December 2011. FDA. 18 May 2013. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm285145.pdf> 13

FDA Notice of Violation and Warning Letters A White Paper, FDA Communications Oversight in a Digital Era: 2008-2013 (April 2013)3 In the absence of formal guidance, the most obvious means of assessing regulatory intent is through the issuance of regulatory action letters by FDA s Office of Prescription Drug Promotion. Of 173 regulatory actions letters issued by the FDA only 1 involved a social media platform. 3. Senak, Mark S. FDA Communications Oversight in a Digital Era: 2008-2013." April 2013. Fleisman-Hillard International Communications. 18 May 2013. < http://www.eyeonfda.com/wp-content/uploads/2013/04/fdacommunications-oversight-in-a-digital-era.pdf >. 14

IRB s and Social Media Most treat advertisements for social media, the same as non-digital advertisements Regulation based on FDA s - Recruiting Study Subjects-Information sheet 4 Protect the safety and privacy of prospective participants and cannot imply : certainty of positive outcome, safety or effectiveness, or free treatment 4. Recruiting Study Subjects - Information Sheet, Guidance for Institutional Review Boards and Clinical Investigators. 18 October 2010. FDA. 18 May 2013. <http://www.fda.gov/regulatoryinformation/guidances/ucm126428.htm > 15

IRB s and Social Media (cont.) Variation between IRBs and what is acceptable Some IRB s decline requests to utilize social media platforms Others allow it, but usability will need to be tailored to each IRB s requirements 16

Considerations for Using Social Media in Clinical Trials Check current government policies Understand your objective and the social media platforms available Evaluate its use and effectiveness for your trial. 17

Social Media Can be a highly effective Tool.

19

References Guidance for Industry : Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices. December 2011. FDA. 18 May 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinfor mation/guidances/ucm285145.pdf Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools. 17 April 2013. FDA. 18 May 2013. http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandt obacco/cder/ucm184250.htm Recruiting Study Subjects - Information Sheet, Guidance for Institutional Review Boards and Clinical Investigators. 18 October 2010. FDA. 18 May 2013. <http://www.fda.gov/regulatoryinformation/guidances/ucm126428.htm > Senak, Mark S. FDA Communications Oversight in a Digital Era: 2008-2013." April 2013. Fleisman-Hillard International Communications. 18 May 2013. < http://www.eyeonfda.com/wp-content/uploads/2013/04/fda- Communications-Oversight-in-a-Digital-Era.pdf >. 18